Identification of a potential sialylation-related pattern for the prediction of prognosis and immunotherapy response in small cell lung cancer

Yao Yu,Yu Shang,Yaowu He,Si Shi,Qi Wang,Jing Ma,Menghan Wang,Wenchao Shi,Hong Chen

DOI: https://doi.org/10.1097/md.0000000000040060

IF: 1.6

2024-10-15

Medicine

Abstract:Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related mortality worldwide. [ 1 ] Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor which accounts for approximately 13% of all lung cancers. [ 2 ] SCLC is a malignant tumor characterized by rapid growth, early invasion, and high dependence on chemotherapy. However, there are significant differences in patient prognosis and sensitivity to immunotherapy in clinical practice. To date, there are no effective targeted drugs for SCLC, which further limits therapeutic options. Platinum-etoposide chemotherapy is still the backbone of standard treatment for SCLC. However, the prognosis of SCLC is the worst among all types of lung cancer, with a 2-year survival rate of <5%. [ 3 ] Even combining the anti-programmed death-1 ligand (anti-PD-L1) monoclonal antibodies atezolizumab and durvalumab with standard chemotherapy in extensive SCLC only prolonged median overall survival about 2 months. [ 4 , 5 ] Therefore, it is particularly important to search for biomarkers that can predict the prognosis and response to immunotherapy in SCLC. One potential biomarker of interest is sialylation patterns, which refer to the modification of glycoproteins and glycolipids by sialic acid. [ 6 , 7 ] Sialylation is known to play crucial roles in various biological processes, including immune responses and cancer progression. [ 8 , 9 ] Recently, studies have suggested that alterations in sialylation patterns may be associated with tumor heterogeneity and therapeutic outcomes in different cancer types. [ 10 , 11 ] Sialylation is involved in many pathological conditions such as embryonic development, neurodevelopment, reprogramming, oncogenesis, and immune responses. [ 10 , 12 ] Several studies have identified that sialylation is involved in the development of many cancers such as pancreatic cancer, colorectal cancer, papillary thyroid cancer, and ovarian cancer. [ 13–16 ] Furthermore, tumor sialylation has been found to correlate with immune suppression and reduced survival in clear cell kidney cancer and squamous cell lung cancer. [ 17 ] Experiments in vivo and vitro indicate that the β-galactoside α2-6-sialyltransferase 1 (ST6Gal-I) may mediate the invasiveness and tumorigenicity of non-small cell lung cancer cells through the Notch1/Hes1/MMPs pathway. [ 18 ]

medicine, general & internal